By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protagonist Therapeutics 

1455 Adams Drive, Suite 2003
Menlo Business Park
Menlo Park  California   94025  U.S.A.
Phone: 650-587-5766 Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Protagonist Therapeutics To Present New Data For PTG-100 And PTG-200 At Digestive Disease Week 2016 5/17/2016 8:12:45 AM
Protagonist Therapeutics Names Thomas P. O'Neil Chief Financial Officer 2/17/2016 6:19:27 AM
Protagonist Therapeutics Initiates Phase 1 Study With Oral Peptide PTG-100 1/8/2016 6:31:53 AM
Protagonist Therapeutics Receives SBIR Funding For Oral IL-23 Receptor Antagonists For Treatment Of Inflammatory Bowel Diseases 9/24/2015 11:09:45 AM
Protagonist Therapeutics Names Richard S. Shames, M.D. As Chief Medical Officer 9/10/2015 7:15:24 AM
Bay Area's Protagonist Therapeutics Fetches $40 Million to Bring Next-Gen IBD Drugs to Trial 7/16/2015 6:05:43 AM
Protagonist Therapeutics Names William A. Hodder As Senior Vice President, Corporate Development 12/18/2014 8:45:04 AM
Protagonist Therapeutics Closes 2nd Tranche Of $18 Million Series B For Advancing Development Candidate To Clinical Trials In 2015 12/4/2014 4:10:51 PM
Protagonist Therapeutics Expands Series B Financing to $18 Million With Addition of $4 Million From Pharmstandard 9/19/2013 6:47:31 AM
Protagonist Therapeutics Pulls in $14 Million, Led by Johnson & Johnson (JNJ), for Peptide Pills 6/4/2013 7:08:11 AM
12
//-->